World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
27194
World Ranking
16997
National Ranking
8524

Overview

Parameswaran Hari is affiliated with the Medical College of Wisconsin in the United States. Their research primarily revolves around the field of Medicine with a focus on Hematology, Oncology, Molecular Biology, Genetics, and Immunology.

The scientist's work covers key topics including:

  • Multiple Myeloma Research and Treatments
  • CAR-T cell therapy research
  • Protein Degradation and Inhibitors
  • Hematopoietic Stem Cell Transplantation
  • Chronic Lymphocytic Leukemia Research
  • Biosimilars and Bioanalytical Methods
  • Cancer Treatment and Pharmacology

Frequent co-authors collaborating with Parameswaran Hari include:

  • Saurabh Chhabra
  • Anita D'Souza
  • Binod Dhakal
  • Mehdi Hamadani
  • Saad Z. Usmani

The scientist has published extensively in several venues. Notable frequent publication venues are:

  • Blood
  • Transplantation and Cellular Therapy
  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Biology of Blood and Marrow Transplantation

Some recent significant papers authored or co-authored by Parameswaran Hari include:

  • Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study (2021), The Lancet
  • Current Use of and Trends in Hematopoietic Cell Transplantation in the United States (2020), Biology of Blood and Marrow Transplantation
  • Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up (2022), Journal of Clinical Oncology
  • Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial (2020), Nature Medicine
  • Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group (2021), The Lancet Oncology

Best Publications

  • Lenalidomide after stem-cell transplantation for multiple myeloma

    Philip L. McCarthy;Kouros Owzar;Craig C. Hofmeister;David D. Hurd

  • Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesus G Berdeja;Deepu Madduri;Saad Z Usmani;Andrzej Jakubowiak

  • Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

    Sagar Lonial;Hans C Lee;Ashraf Z Badros;Suzanne Trudel

  • Current Use and Trends in Hematopoietic Cell Transplantation in the United States

    Anita D'Souza;Anita D'Souza;Stephanie Lee;Stephanie Lee;Xiaochun Zhu;Marcelo Pasquini;Marcelo Pasquini

  • Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

    Shaji Kumar;Ian Flinn;Paul G. Richardson;Parameswaran Hari

  • Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

    Ujjawal H. Gandhi;Robert F. Cornell;Arjun Lakshman;Zhubin J. Gahvari

  • Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

    Nirav N. Shah;Bryon D. Johnson;Dina Schneider;Fenlu Zhu

  • Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial

    Amrita Krishnan;Marcelo C Pasquini;Brent Logan;Edward A Stadtmauer

  • Long-Term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

    Mohamed L. Sorror;Brenda M. Sandmaier;Brenda M. Sandmaier;Barry E. Storer;Barry E. Storer;Georg N. Franke

  • Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

    Shaji K. Kumar;Jesus G. Berdeja;Ruben Niesvizky;Sagar Lonial

  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    S. K. Kumar;M. A. Dimopoulos;E. Kastritis;E. Terpos

  • Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.

    Nilanjan Ghosh;Reem Karmali;Vanderson Rocha;Kwang Woo Ahn

  • PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: High response rate but frequent GVHD

    Bradley M. Haverkos;Diana Abbott;Mehdi Hamadani;Philippe Armand

  • Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma

    Sonali M. Smith;Linda J. Burns;Koen W. van Besien;Jennifer LeRademacher

  • Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Dan T Vogl;Noopur S Raje;Sundar Jagannath;Paul G. Richardson

  • Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

    Edward A. Stadtmauer;Marcelo C. Pasquini;Beth Blackwell;Parameswaran Hari

  • Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation

    Rainer Storb;Boglarka Gyurkocza;Boglarka Gyurkocza;Barry E. Storer;Barry E. Storer;Mohamed L. Sorror;Mohamed L. Sorror

  • Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

    Javier Bolaños-Meade;Ran Reshef;Raphael Fraser;Mingwei Fei

  • Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

    Maria-Victoria Mateos;Hilary Blacklock;Fredrik Schjesvold;Albert Oriol

  • Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

    Shaji Kumar;Meletios A Dimopoulos;Efstathios Kastritis;Evangelos Terpos

Frequent Co-Authors

Marcelo C. Pasquini
Marcelo C. Pasquini Medical College of Wisconsin
Mei-Jie Zhang
Mei-Jie Zhang Medical College of Wisconsin
Shaji Kumar
Shaji Kumar Mayo Clinic
Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
Saad Z. Usmani
Saad Z. Usmani Memorial Sloan Kettering Cancer Center
David G. Maloney
David G. Maloney Fred Hutchinson Cancer Research Center
William R. Drobyski
William R. Drobyski Medical College of Wisconsin
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Sagar Lonial
Sagar Lonial Emory University
Brenda M. Sandmaier
Brenda M. Sandmaier Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in medical careers but want flexible study options, several accredited online degrees can help you launch or advance your healthcare journey. For Registered Nurses seeking to specialize, rn to fnp bridge programs offer a direct route from RN to Family Nurse Practitioner, supporting career growth without requiring a traditional campus setting.

For those passionate about diet, health, and wellness, earning a nutritionist online degree is a versatile way to build expert knowledge in nutrition science and qualify for rewarding roles in healthcare or the food industry.

If healthcare management is your goal, it's vital to know how to evaluate healthcare administration degree programs. Look for programs with CAHME accreditation to ensure high educational standards and optimal career outcomes.

Finally, RNs wishing to advance without on-site clinicals can consider online rn to bsn programs without clinicals. These programs offer flexible scheduling for licensed professionals eager to boost their credentials while balancing work or family commitments.

Best Scientists Citing Parameswaran Hari

Trending Scientists

Recently Published Articles